Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Synthetic DNA vaccine strategies against persistent viral infections.Expert review of vaccines · 2013
   Review
2. T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.Journal of global infectious diseases · 2011
   Article
3. Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine.Journal of virology · 2010
   Article
4. Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.Vaccine · 2008
   Article
5. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Journal of virology · 2008
   Review
6. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.Infection and immunity · 2008
   Article

Corrections and comments

• Comment on
  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.2006
• Comment on
  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.2006

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as